Document is current
Any future updates will be listed below
-
Authors
Schiestl, Martin https://orcid.org/0000-0001-5784-9951
Roy, Nivedita
Trieb, Michael
Park, Joseph P.
Guillen, Elena
Woollett, Gillian https://orcid.org/0000-0002-9336-2769
Wolff-Holz, Elena https://orcid.org/0000-0002-8129-7381
- License Information
-
More Information
Article History
Accepted: 6 July 2025
First Online: 17 July 2025
Declarations
:
: No funding was received for this review.
: The authors, with the exception of Elena Guillen, are employed by companies developing and/or marketing biosimilar medicines. Gillian Woollett is an Editorial Board member of BioDrugs. Gillian Woollett was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Elena Wolff-Holz is an Editorial Board member of BioDrugs. Elena Wolff-Holz was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MS had the idea for the article. All authors contributed to the drafting, data analysis, review, and final approval of the manuscript.
